| Nov 5 |
Arcellx to Present Clinical Data for Its Phase 1 and iMMagine-1 Studies in Patients with Relapsed or Refractory Multiple Myeloma at the 66th ASH Annual Meeting and Exposition and Announces Progress in iMMagine-3 Study
|
| Nov 5 |
Cancer cell therapy from Arcellx, Gilead shows promise in early data
|
| Nov 1 |
Arcellx (ACLX) Surged in Q3. Here’s Why
|
| Oct 9 |
Is Boston Scientific (BSX) Stock Outpacing Its Medical Peers This Year?
|
| Sep 10 |
Arcellx's Anito-Cel: Compelling Opportunity As Potential Best-In-Class CAR-T Therapy For Multiple Myeloma
|
| Aug 9 |
Arcellx GAAP EPS of -$0.51, revenue of $27.38M
|
| Aug 8 |
Arcellx, Inc. (ACLX) Reports Q2 Loss, Misses Revenue Estimates
|
| Aug 8 |
Arcellx Provides Second Quarter 2024 Financial Results and Business Updates
|
| Aug 2 |
Here’s Why Arcellx (ACLX) Slipped in Q2
|
| Aug 2 |
A Look At The Intrinsic Value Of Arcellx, Inc. (NASDAQ:ACLX)
|
